| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.2146/AJHP140168 |
| P698 | PubMed publication ID | 25694411 |
| P2093 | author name string | Eva M Vivian | |
| P2860 | cites work | Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes | Q24642503 |
| Current perspectives in bladder cancer management | Q26824914 | ||
| Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group | Q27860882 | ||
| Standards of medical care in diabetes--2014 | Q28304435 | ||
| Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group | Q29547282 | ||
| Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes | Q30548796 | ||
| Defining and characterizing the progression of type 2 diabetes | Q33610728 | ||
| Anatomical and developmental patterns of facilitative glucose transporter gene expression in the rat kidney | Q33897182 | ||
| American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement--executive summary | Q34081331 | ||
| SGLT2 inhibition--a novel strategy for diabetes treatment | Q34117872 | ||
| Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications | Q34120717 | ||
| The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose | Q34121476 | ||
| Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial | Q34153496 | ||
| The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus | Q34315521 | ||
| Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence | Q34321390 | ||
| Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus | Q47766554 | ||
| Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years | Q47871792 | ||
| Urinary tract infections in patients with diabetes treated with dapagliflozin | Q48016891 | ||
| Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study. | Q51332473 | ||
| Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin. | Q51335341 | ||
| Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. | Q51359456 | ||
| Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. | Q51372081 | ||
| Quantifying the risk of infectious diseases for people with diabetes | Q78841126 | ||
| Uric acid and cardiovascular risk | Q79689991 | ||
| Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects | Q82651893 | ||
| Lack of pharmacokinetic interactions between dapagliflozin and simvastatin, valsartan, warfarin, or digoxin | Q83310339 | ||
| Effect of a high-fat meal on the pharmacokinetics of dapagliflozin, a selective SGLT2 inhibitor, in healthy subjects | Q83703955 | ||
| Pharmacokinetics, metabolism, and excretion of the antidiabetic agent ertugliflozin (PF-04971729) in healthy male subjects | Q85497609 | ||
| Dapagliflozin added to usual care in individuals with type 2 diabetes mellitus with preexisting cardiovascular disease: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension | Q88008831 | ||
| SGLT2 mediates glucose reabsorption in the early proximal tubule. | Q34457264 | ||
| Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level | Q34575066 | ||
| Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial | Q34593046 | ||
| Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study | Q34720231 | ||
| Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members | Q35111563 | ||
| Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial | Q35179843 | ||
| Pathogenesis and management of bacterial urinary tract infections in adult patients with diabetes mellitus | Q35550887 | ||
| Microvascular complications of impaired glucose tolerance. | Q35591509 | ||
| Phlorizin: a review | Q35995949 | ||
| Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy | Q36047253 | ||
| LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. | Q36105649 | ||
| Targeting the kidney and glucose excretion with dapagliflozin: preclinical and clinical evidence for SGLT2 inhibition as a new option for treatment of type 2 diabetes mellitus | Q36175431 | ||
| The prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes, 1988-2010. | Q37022665 | ||
| Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes | Q37139427 | ||
| Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes | Q37193454 | ||
| Association between serum uric acid and development of type 2 diabetes. | Q37319097 | ||
| A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment | Q37319128 | ||
| Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications | Q37439364 | ||
| Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice? | Q37475726 | ||
| Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes | Q37532095 | ||
| Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control | Q37679893 | ||
| Inhibition of SGLT2: a novel strategy for treatment of type 2 diabetes mellitus | Q37846528 | ||
| Glucose handling by the kidney | Q37848041 | ||
| Insulin treatment for type 2 diabetes: when to start, which to use. | Q37871231 | ||
| SGLT inhibitors in management of diabetes | Q38195440 | ||
| Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats | Q39999985 | ||
| Increasing cardiovascular disease burden due to diabetes mellitus: the Framingham Heart Study | Q42165604 | ||
| Learning from glycosuria | Q42641850 | ||
| The novel sodium glucose transporter 2 inhibitor dapagliflozin sustains pancreatic function and preserves islet morphology in obese, diabetic rats | Q42873604 | ||
| Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial | Q42977455 | ||
| In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans | Q43227334 | ||
| Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose-finding study. | Q43755014 | ||
| Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia | Q45442620 | ||
| Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus | Q46171591 | ||
| Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects | Q46171594 | ||
| Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin | Q46401612 | ||
| Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models | Q46516165 | ||
| Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial | Q46595958 | ||
| P433 | issue | 5 | |
| P921 | main subject | dapagliflozin | Q409898 |
| glycobiology | Q899224 | ||
| type 2 diabetes | Q3025883 | ||
| P304 | page(s) | 361-372 | |
| P577 | publication date | 2015-03-01 | |
| P1433 | published in | American Journal of Health-System Pharmacy | Q15754037 |
| P1476 | title | Dapagliflozin: a new sodium-glucose cotransporter 2 inhibitor for treatment of type 2 diabetes | |
| P478 | volume | 72 |
| Q64069337 | Assessment of Dapagliflozin Effectiveness as Add-on Therapy for the Treatment of Type 2 Diabetes Mellitus in a Qatari Population |
| Q36180337 | Cost-Effectiveness of Dapagliflozin versus Acarbose as a Monotherapy in Type 2 Diabetes in China |
| Q39451601 | Cost-effectiveness analysis of dapagliflozin versus glimepiride as monotherapy in a Chinese population with type 2 diabetes mellitus |
| Q49963693 | Dapagliflozin Reduces Fat Mass without Affecting Muscle Mass in Type 2 Diabetes |
| Q38651175 | Diabetes drugs and the incidence of solid cancers: a survey of the current evidence. |
| Q37227410 | Renal threshold for glucose reabsorption predicts diabetes improvement by sodium-glucose cotransporter 2 inhibitor therapy |
Search more.